

INFORME DE BÚSQUEDA DE PATENTES PARA EL Radicado N° 14-58208-00003-0000						
CRITERIOS PARA LA BÚSQUEDA (anexar pantallazo o reporte en PDF, junto con los boleanos utilizados)						
Palabras clave utilizadas		Antibody anti – Guanylyl cyclasa C (GCC; ST receptor), immunoconjugates treating for colon cancer				
CLASIFICACIONES INTERNACIONALES UTILIZADAS PARA LA BÚSQUEDA		A61K 39/395				
BASES DE DATOS CONSULTADAS.						
Patentscope		Google/patents				
NCBI		Epoquenet				
Espacenet						
Lens						
INFORMES DE EXÁMENES REALIZADOS EN OTRAS OFICINAS (documentos patentes, literatura no patente etc...)						
Oficina	Fecha del examen o de reporte de búsqueda de documentos	Anterioridades encontradas para el examen o reportados en el examen de búsqueda(relacionarlos todos)	Reiv. afectadas	RELEVANCIA (requisito que afecta)	FUERON TENIDOS EN CUENTA PARA EL EXAMEN EN LA OFICINA COLOMBIANA	
					SI	NO
PCT INTERNATIONAL SEARCH REPORT EPO	30/Diciembre /2010	NANDI, A. <i>et al.</i> , 1997. "Epitope Conservation and Immunohistochemical Localization of the Guanylin/Stable Toxin Peptide Receptor, Guanylyl Cyclase C.," Journal of Cellular Biochemistry, Vol. 66, No. 4, pages 500-511.	1 - 15	Documento tipo A		X
		US6268159	1 - 15	Documento tipo A	X	
		DORONINA SVETLANA O, <i>et al.</i> , 2008. Novel peptide linkers for highly potent antibody-auristatin conjugate. Publication. BIOCONJUGATE CHEMISTRY, 20081001 ACS, WASHINGTON, DC, US. Source info:Vol: 19, Nr: 10, Page(s): 1960 - 1963	6 - 8	Documento tipo A		X
DOCUMENTOS ADICIONALES ENCONTRADOS POR EL EXAMINADOR DE ACUERDO A LOS CRITERIOS DE BÚSQUEDA.						
Nandi Animesh, Bhandari Rashna, Visweswariah Sandhya S, 1997. Epitope conservation and immunohistochemical localization of the guanylin/stable toxin peptide receptor, guanylyl cyclase C						
Singh <i>et al.</i> , 1991. "Isolation and expression of a guanylate cyclase-coupled heat stable enterotoxin receptor cDNA from a human colonic cell line."						
Snook <i>et al.</i> , 2008. "Guanylyl Cyclase C- Induced Immunotherapeutic Responses Opposing Tumor Metastases Without Autoimmunity".						
Urbanski <i>et al.</i> , 1195. "Internalization of E. coli ST mediated by guanylyl cyclase C in T84 human colon carcinoma cells"						
Vaandrager <i>et al.</i> , 1993. "Guanylyl cyclase C is an N-linked glycoprotein receptor that accounts for multiple heat-stable enterotoxin-binding proteins in the intestine."						
US7854933						
US8067007						
WO2004071436						
US6060037						
US6602659						
US6767704						
WO2005101017						
BÚSQUEDA DE SECUENCIAS						

Número de depósito / patente y N° de secuencia % de identidad					
SEQ ID NO (de la solicitud)	NCBI	The Lens	EMBL-EBI	DDJB	Genome Quest

Búsqueda de Secuencias

SEC ID NO: 18

Sequences producing significant alignments:

Select: [All](#) [None](#) Selected: 0

[Alignments](#) [Download](#) [GenPept](#) [Graphics](#) [Distance tree of results](#) [Multiple alignment](#)

	Description	Max score	Total score	Query cover	E value	Ident	Accession
☐	Sequence 18 from patent US 8785600	398	398	100%	3e-130	100%	AJM41920.1
☐	Sequence 231 from patent US 8785600	398	398	100%	1e-120	100%	AJM42028.1
☐	Sequence 567 from patent US 7973140	345	345	100%	3e-109	90%	AEK15281.1
☐	Sequence 185 from patent US 7521048	335	335	100%	5e-105	90%	ACR85191.1
☐	Sequence 290 from patent US 8840894	335	335	100%	6e-105	89%	AJN09595.1
☐	Sequence 179 from patent US 8828382	335	335	100%	7e-105	89%	AJN01032.1
☐	Sequence 2 from patent US 6787638	337	337	100%	2e-104	89%	AAW03903.1
☐	Sequence 180 from patent US 8828382	333	333	100%	3e-104	88%	AJN01033.1
☐	unnamed protein product [synthetic construct]	332	332	100%	6e-104	89%	CAL14845.1
☐	Sequence 88 from patent US 8030457	331	331	100%	1e-103	88%	AEQ82323.1

US 8785600 es la misma solicitud

SEC ID NO: 20

Sequences producing significant alignments:

Select: [All](#) [None](#) Selected: 0


[Alignments](#) [Download](#) [GenPept](#) [Graphics](#) [Distance tree of results](#) [Multiple alignment](#)

	Description	Max score	Total score	Query cover	E value	Ident	Accession
☐	Sequence 20 from patent US 8785600	353	353	100%	3e-114	100%	AJM41921.1
☐	Sequence 233 from patent US 8785600	353	353	100%	3e-107	100%	AJM42029.1
☐	Sequence 64 from patent US 8026344	333	333	100%	3e-106	95%	AEP61983.1
☐	Sequence 638 from patent US 7973140	333	333	100%	3e-106	95%	AEK15352.1
☐	Sequence 6 from patent US 6924360	332	332	100%	9e-106	95%	ABA32325.1
☐	Sequence 30 from patent US 7767206	330	330	100%	8e-105	94%	ADS19553.1
☐	Sequence 74 from patent US 8207306	329	329	100%	2e-104	94%	AFQ19046.1
☐	Sequence 122 from patent US 7306906	328	328	100%	3e-104	94%	ABY14804.1
☐	Sequence 29 from patent US 7973140	327	327	100%	9e-104	93%	AEK15007.1
☐	Sequence 132 from patent US 7306906	325	325	100%	7e-103	94%	ABY14814.1

US 8785600 es la misma solicitud

Búsqueda en EPOQUENET

EPODOC	SS Status	Results	Query
1		27	ANTIBODY AND AURISTATIN AND CONJUGATE
2		468	GCC
3		0	1 AND 2
4		268.071	ANTIBOD[Y, IES] OR POL[Y, I]PEPTI+
5		55	2 AND 4
6	Sel SS 1	27	..SEL SS 1



WO2006034488 NZ580115 NZ553500 US2015017188 US2011137017

EPDOC / EPO

PN - WO2006034488 A2 20060330
PNFP - WO2006034488 A3 20060928
TI - (A2 A3)
TI FR - CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES
TI FR - (A2 A3)
TI FR - ANTICORPS ET CONJUGUÉS PRODUITS AVEC DE LA CYSTÉINE
AB - (A2)
 Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)_{sub}
 - (A3)
 Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of

Figure 2

Diagram of a cysteine engineered antibody structure showing various amino acid residues labeled: V15C, A43C, A40C, A88C, S119C, A121C, S122C, S179C, A175C, A144C, V110C, S168C.